

Investor Presentation

ProPhaseLabs.com
NASDAQ: PRPH

FORWARD LOOKING STATEMENTS

Except for the historical information contained herein, this document contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including our expectation to enter into new agreements for Pharnaloz, our expectations regarding the future revenue growth potential of each of our subsidiaries, our expectations regarding future liquidity events, the expected timeline for commercializing our BE-Smart Esophageal Cancer Test, our ability to enter into new domestic and international long-term contracts for our Nebula Genomics business and the financial impact of any such contracts, the anticipated timing for the receipt of new equipment and installation of additional lozenge lines and their ability to increase capacity and revenue, our anticipated expenses, ability to obtain funding for our operations and the sufficiency of our cash resources, and the expected timeline for the launch of Equivir capsules. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment, and the risk factors listed from time to time in our Annual Report on Form 10-K for the year ended December 31, 2023, our subsequent Quarterly Reports on Form 10-Q and any other filing with the Securities and Exchange Commission. These forward-looking statements are based on current expectations, estimates, forecasts and projections and are not guarantees of future performance or development. The Company undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance and are cautioned not to place undue reliance on any forward-looking statements.

MARKET AND INDUSTRY DATA

This presentation includes market and industry data and forecasts that the Company has derived from independent consultant reports, publicly available information, various industry publications, other published industry sources, and its internal data and estimates. Independent consultant reports, industry publications and other published industry sources generally indicate that the information contained therein was obtained from sources believed to be reliable. Although the Company believes that these third-party sources are reliable, it does not guarantee the accuracy or completeness of this information, and the Company has not independently verified this information. The Company's internal data and estimates are based upon information obtained from trade and business organizations and other contacts in the markets in which the Company operates and management's understanding of industry conditions. Although the Company believes that such information is reliable, it has not had this information verified by any independent sources.

FREE WRITING PROSPECTUS

This presentation should be read together with the preliminary prospectus supplement dated November 7, 2024 (the "Preliminary Prospectus Supplement") and the accompanying base prospectus dated November 12, 2021 (the "Base Prospectus"), included in the Registration Statement on Form S-3 (File No. 333-260848) (the "Registration Statement"). This presentation highlights basic information about us. Because it is a summary, it does not contain all of the information that you should consider in making an investment decision. Before you invest you should read the Preliminary Prospectus Supplement, the Base Prospectus and the Registration Statement (including the Risk Factors described therein) and other documents we have filed with the Securities and Exchange Commission ("SEC") for more complete information about us and the proposed offering.

You may access these documents for free by visiting EDGAR on the SEC Web site at <http://www.sec.gov>. The Preliminary Prospectus Supplement and the Base Prospectus can be accessed on the SEC's website through the following link at <http://www.sec.gov>. Alternatively, we or any underwriter participating in the offering will arrange to send you the prospectus if you contact ThinkEquity, Prospectus Department, 17 State Street, 41st Floor, New York, New York 10004, telephone: (877) 436-3673.

This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction. The offering will only be made by means of a prospectus supplement and related base prospectus.



3

PROPHASE LABS BUSINESS VERTICALS

Pharmaloz, one of the largest lozenge manufacturing facilities and Contract Development and Manufacturing Organization (CDMO). Exploring strategic alternatives, including a sale.

ProPhase BioPharma includes BE-Smart investigational esophageal cancer test, a potentially ground-breaking early detection esophageal cancer diagnostic test, with a target market of \$7-14 billion¹. Collaborating with a world-class consultant to attain a potential strategic partnership with one of numerous, large cancer diagnostic companies in 2025 as well as commercialize either as a laboratory developed test (LDT) or in compliance with the applicable FDA requirements.

DNA Complete, a world-class Whole Genome Sequencing and Bioinformatics DTC test offering. Launching a comprehensive marketing campaign in collaboration with a proven marketing leader, to include social media influencers, etc.

Nebula Genomics, a world-class genomics laboratory based in Garden City, NY. Multiple state-of-the-art sequencing platforms.

ProPhase Supplements, which includes Legendz XL, which is in major food, drug and mass stores, Triple Edge XL, and soon to be introduced Equivir. Plan to leverage the online marketing platform built for DNA Complete.

Committed to executional excellence, smart diversification, and a synergistic, omni-channel approach

Pharmaloz
Manufacturing, Inc.

ProPhase
BIOPHARMA
BE-Smart

DNA Complete

Nebula
Genomics


ProPhase
Supplements



¹Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2021 - Gastroenterology ([gastrojournal.org](https://www.gastrojournal.org))

4

OUR BEST IS YET TO COME! PERFORMANCE TRACK RECORD



*Management's analysis and guidance announced by ProPhase Labs on January 23, 2024: <https://www.globenewswire.com/en/news-release/2024/01/23/2814037/0/en/Pharmaloz-Manufacturing-Accelerates-Expansion-Improves-Pricing-Boosts-Profitability-and-Secures-New-Contracts.html>



Pharmaloz
Manufacturing, Inc.

THE PHARMALOZ MANUFACTURING FACILITY

One of the Largest Lozenge Manufacturer in the U.S.

Lozenge Contract Manufacturing – Approx. 60,000 sq. ft. climate-controlled facility on 12 acres operating under FDA 21 CFR 210 & 211 guidelines provides the ability to offer products for diversified needs.

Private Label – Partnering with our brokers and retailers to provide their best quality products.

Research & Development – Develops and formulate customers' unique, best in class products

Marketing - Offers the ability to deploy various strategies to help customers market their products successfully.

Shipping, packing and distribution logistics - Able to service over 40,000 food, drug and mass stores in the United States.

Quality & Regulatory - Embraces the importance of both Quality & Regulatory compliance throughout the manufacturing process.



7

NEW STRATEGIC INITIATIVES CREATE OPPORTUNITIES FOR LIQUIDITY AND VALUE CREATION*

Hired ThinkEquity investment bank to explore strategic alternatives including a potential sale of Pharmaloz Manufacturing.*

Growing customers and expanding production capacity.

Signed two top-tier lozenge brands adding an additional \$5mm annualized revenues with strong profit margins*.

In late-stage discussions to add several new brands.

Increased prices on all customers effective Q1 2024.

Starting in January 2025, a large new customer is expected to start production of a non-seasonal lozenge, improving off-season business.

Lozenge manufacturing line #2 is built and to be delivered.

Lozenge line #3 planned for H2 2025, which would increase capacity.

The new lines are highly automated, require less labor and are therefore expected to deliver both increased revenues and improved margins.



*<https://ir.prophaselabs.com/news-events/press-releases/detail/214/prophase-labs-announces-update-on-pharmaloz-manufacturing>

8



BE-Smart™ ESOPHAGEAL CANCER DIAGNOSTIC IN DEVELOPMENT

ESOPHAGEAL ADENOCARCINOMA (EAC) – ONE OF THE DEADLIEST CANCERS

- 16,000+ Estimated Deaths in 2023 in the U.S.¹
- 78.3% - 5-Year Mortality Rate (2013-2019)¹
- 21,000+ Estimated New Cases in 2023¹
- The change in the annual incidence of EAC was 766.67% higher in 2017 compared to 1973²
- Journal of American Medical Association once again reported that GI cancers for the 2nd straight decade are the fastest growing cancer type in America³

Gastroesophageal Reflux Disease (GERD) occurs when stomach acid repeatedly flows back into the esophagus. Backwash (acid reflux) can irritate the lining of esophagus. Many experience acid reflux from time to time; for some, GERD may trigger a change in the cells lining the lower esophagus causing **Barrett's Esophagus**.

Barrett's Esophagus - Esophagus becomes damaged by acid reflux; causes the lining to thicken and become red. Associated with increased risk of developing **Esophageal Adenocarcinoma**.

Discovering pre-cancerous tissue in early and treatable stages may increase disease survival and decrease cost of care. As high as 40% of esophageal carcinoma is missed or found late leading to more unfavorable diagnosis.



- 1- <https://bit.ly/40ONuqt> - Cancer Stat Facts: Esophageal Cancer
- 2- <https://bit.ly/3KGWGr9> - Epidemiology of early esophageal adenocarcinoma
- 3- <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2808381>

OPPORTUNITY TO PREVENT ESOPHAGEAL CANCER WITH EARLY AND ACCURATE DIAGNOSIS

Prevalence of GERD in the U.S. of 20%¹ (Census 337 million²)

~ 67 million

Prevalence of Barrett's Esophagus in the U.S. is 5.6% of the population³ (Census 337 million²)

~ 18 million

New Cases of Esophageal Adenocarcinoma in U.S. per year⁴

~ 20K

Endoscopy (upper) related to GERD and Barrett's Esophagus average⁵

~ 7 million

1- <https://www.ncbi.nlm.nih.gov/books/NBK441938/>

2- <https://www.census.gov/popest/>

3- <https://www.aajp.org/pubs/ajp/2022/1000/barrett-esophagus.html#:~:text=Barrett%20esophagus%20is%20estimated%20to,Barrett%20esophagus%20or%20esophageal%20adenocarcinoma>

4- <https://pmc.ncbi.nlm.nih.gov/articles/PMC10007944/#:~:text=Carcinoma%20of%20esophagus%20is%20the,for%2016%2C410%20deaths%20>

5- <https://linkinghub.elsevier.com/retrieve/pii/S0016508521036556>

Target Market Endoscopies:

~7mm

Estimated average cost per test:

\$1k - \$2k

Total Potential Addressable Market:

~\$7b - \$14b

11

ADVANTAGES OF THE BE-Smart™ ESOPHAGEAL CANCER DIAGNOSTIC COMPARED TO LIQUID BIOPSIES

- ✓ BE-Smart is designed to take EXISTING biopsy blocks from routine endoscopies, which is the standard of care for diagnosis of GERD, Barrett's Esophagus and esophageal adenocarcinoma. No additional samples are needed from patients after the endoscopy. With liquid biopsies, the patient would have to return to the physician's office to draw the blood.
- ✓ BE-Smart is highly sensitive and specific in distinguishing early-stage esophageal adenocarcinoma in studies to date. On the other hand, liquid biopsies require the cancer to spread to neighboring tissue and blood vessels in order to produce detectable markers in the blood.
- ✓ Our BE-Smart test examines the suspicious tissue DIRECTLY, not a bi-product somewhere in the blood. In liquid biopsies, there are factors that can create many false positives and false negatives as the tested markers are at very low concentrations. These factors can be other pathological and non-pathological conditions, including exercise, trauma, and surgery.¹
- ✓ We are testing the affected tissue directly on a clinically proven instrument (mass spectrometer), which is highly sensitive.
- ✓ By directly analyzing the affected tissue, the BE-Smart test is designed to detect early stages of cancer before markers have entered the blood.
- ✓ While we are still studying the test's safety and effectiveness, we believe that the BE-Smart test may have the ability to determine early carcinogenesis. FDA Approved liquid biopsy tests on the market are used to monitor a disease or to determine treatment path of a disease. They are still required to be used in combination with standard tests such as endoscopies.

Conclusion: The utility of BE-Smart is potentially quite significant. The BE-Smart test is designed to determine early carcinogenesis of biopsies in which a pathologist might be on the fence and/or mistakenly classify as non-cancerous. This can literally mean the difference between life and death for the patient. An accurate and early diagnosis can lead to more effective and earlier treatments which can lead to significantly better outcomes for the patient.

1. Braig D., Becherer C., Bickert C., Braig M., Claus R., Eisenhardt A.E., Heinz J., Scholber J., Herget G.W., Bronsert P., et al. Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas. *Int. J. Cancer*. 2019;145:1148-1161. doi: 10.1002/ijc.32216.

12

BE-Smart™ - ESOPHAGEAL CANCER DIAGNOSTIC

ProPhase is collaborating with Forward Healthcare Consultants (FHC) to bring its BE-Smart esophageal cancer test to market. FHC will assist with securing market access by focusing on coverage, pricing and coding. Additionally, FHC will bring its vast relationships with physician networks to drive commercialization success.* In parallel, in collaboration with FHC, Company has begun exploring potential partnerships with multi-billion-dollar cancer diagnostic testing companies.

FHC is a world-renowned consulting company that has provided its support to a litany of pharmaceutical companies and helped them grow from small start-ups with development stage products to multi-billion-dollar enterprises with industry leading diagnostic applications.

Continued refining the BE-Smart test algorithm with new data analysis, enhancing its accuracy in predicting Barrett's Esophagus risk.

Receiving an additional set of samples from Mayo Clinic to run a larger data set and learn not just the core proteins associated with EAC but also other potential targets for future use in therapeutic applications. Collaborating with Mayo Clinic and other experts to further validate the test through additional studies and peer-reviewed publications.



*Source: Company Press Release, August 13, 2024: <https://ir.prophaselabs.com/news-events/press-releases/detail/216/prophase-labs-announces-collaboration-with-forward>

13

BE-Smart™ - ESOPHAGEAL CANCER DIAGNOSTIC NEAR TERM PATH TO COMMERCIALIZATION

- ✓ Filed US patent application on May 19, 2021
- ✓ Initiated 1,000 patients on STLA101 assay with Mayo Clinic
- ✓ Completed first ~200 tests
- ✓ Submitted and presented interim results to ACG/ASCO-GI/SAGES/AACR/DDW in 2022
- ✓ Filed all patent applications for all significant international jurisdictions
- ✓ Initiated testing of additional specimens, including brush-acquired ones
- ✓ Collaborated with brush-technology company to develop brush-capture technique to replace the need for endoscopy
- ✓ Expanded support from key opinion leaders at conferences (including USCAP) and in focus groups
- ✓ US Patent 11,874,277 granted protecting BE-Smart
- ✓ Published first validation specific to BE-Smart, finding that its "proteomic panel is comprised of predictive biomarkers that are both statistically significant and mechanistically meaningful"
- ✓ Completion of BE-Smart Dossier
- ☐ Continuation of Mayo clinic collaboration with 100 additional samples
- ☐ Complete Commercialization Planning
- ☐ Conduct Customer Research
- ☐ Launch Clinical Testing
- ☐ Initiate discussions with payers for coverage in medical policy
- ☐ Go-to-market strategy:
 - Commercialize with a large pharma or cancer-testing company
 - Work on global commercialization initiatives in parallel
 - Work with insurance companies to cover BE-Smart and contract for reimbursement

14



DNA COMPLETE® - LAUNCHED ON NOVEMBER 4, 2024

DNA Complete is a world-class Whole Genome Sequencing and Bioinformatics direct to consumer test offering.

Whole Genome Sequencing (“WGS”) Technology

Our WGS DNA technology analyzes virtually 100% of your DNA compared to typical DNA Ancestry tests that analyze less than 1% of your DNA, at a competitive price. This provides more accurate and in-depth health and ancestry reports.

DNA Complete sequences specimens at Nebula Genomics, another wholly owned subsidiary of ProPhase Labs, as well as at other laboratories.

Proprietary Bioinformatics Platform

340+ personalized health pre-disposition reports covering Longevity, Mental Health, Cancer & more.

New Advanced Ancestry platform

Comprehensive ancestry analysis that provides personalized ancestry reports, such as Regional ancestry, Ancestry timeline, Comparison with ancient populations & more.

Data Security

No Third-Party Access to Genomic Data:

DNA Complete ensures that no third parties have access to back-end raw genomic data. All genomic information is securely stored within our infrastructure and is not shared with external entities.

Data Storage and Encryption:

All genomic data is securely stored on AWS (Amazon Web Services) and is encrypted both at rest and in transit, using industry-leading encryption protocols to ensure the highest level of security and privacy.

No Data Sharing for Research or Monetization:

DNA Complete does not share raw genomic data with third parties research companies, for studies or any other purpose. We maintain full control of the data, ensuring it is used solely for the benefit of our users, with no external monetization or unauthorized access.

DNA COMPLETE®

Direct To Consumer Launch of DNA Complete

Shape The Future of Your Health and Explore Your Ancestry with DNA Complete

- Built a comprehensive marketing campaign featuring top influencers, managed by an experienced marketing leader with a proven track record in building global brands. Launching Q4 2024.
- The new offering is designed to deliver a robust genetic user platform, industry-leading pricing and faster turnaround times.
- This new product harnesses our cutting-edge bioinformatics platform and the launch of our proprietary advanced Ancestry platform, offering customers deep analysis of their genomic data.
- Offering genetic counseling services, enhancing the value proposition for customers.



	Essential DNA Test \$195	Pro DNA Test \$495	Elite DNA Test \$1,495
Amount of DNA Analyzed	1X WGS	30X WGS	100X WGS
Accuracy	High accuracy	Higher accuracy	Maximum accuracy
First year of membership included	✓	✓	✓
New Reports + Existing Report Updates	✓	✓	✓
Essential Ancestry Reports	✓	✓	✓
Advanced Ancestry Reports		✓	✓
New Reports Per Month	Up to 3	Up to 5	Up to 10
Total Personalized Health Reports Provided	175+ and counting	250+ and counting	Up to 350+ and counting

DNA EXPAND™

DNA Upload, Expansion and Analysis

- Consumers effortlessly upload their DNA data from other DNA Ancestry tests to unlock our proprietary reports and advanced features.
 - Low cost offering for consumers, makes it a highly attractive offer.
 - Significant gross profit margins presents enormous profit opportunity.
- Expands your DNA data: user's file is boosted with 50x more data after upload, to provide them with significantly more in-depth health and wellness reports compared to typical DNA ancestry tests.
- No need to be tested again. Millions of consumers can easily upload their DNA Ancestry test data from their previous testing. Therefore, DNA Expand can offer low prices while still achieving highly attractive margins.



	DNA Expand™ Powered by Nebula Genomics	Most Other DNA Data Upload Services
DNA data expansion. Expands raw DNA data more than 50 times to over 35 million genetic variants.	✓	✗ No DNA data expansion.
Superior trait reports. More comprehensive trait reports enabled by DNA data expansion.	✓	✗ Limited trait reports.
New Dynamic Reports. Receive frequent new reports that are based on the latest scientific discoveries.	✓	✗ Reports are updated very rarely.
Privacy First DNA Testing. Technology that enables users to have full ownership and control over their genomic data.	✓	✗ Sell customer genomic data.
Diverse, Extensive Database. Built over the last 6 years from whole genome sequencing tests spanning more than 130 countries, and equivalent to roughly 150 million ancestry SNP-based tests.	✓	✗ Not nearly as extensive.




NEBULA GENOMICS

Mission: To usher in the era of personal genomics by providing access to affordable and secure Whole Genome Sequencing ("WGS").

Low-cost laboratory provider of WGS:

B2B Partners include:

- DNA Complete
- Academic Research Centers
- Clinical Research Organizations
- Pharmaceutical Companies
- Physicians' offices
- Telemedicine platforms
- Healthcare Systems
- U.S. and international clients
- Longevity clinics
- Labs without internal sequencing



About George Church, Co-Founder

George Church, Ph.D. is a professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard University and the Massachusetts Institute of Technology (MIT). His pioneering work has contributed to the development of DNA sequencing and genome engineering technologies for which he received multiple awards. He co-authored over 550 publications, more than 150 patents, and a book titled *Regenesis: How Synthetic Biology Will Reinvent Nature and Ourselves*. He initiated the Personal Genome Project and started over 20 companies. In 2017, Dr. Church was celebrated as one of *Time Magazine's* "100 Most Influential People."

SIGNIFICANT NEBULA ASSETS



World class, state-of-the-art, 30,000 SF laboratory in the U.S.



Platform Agnostic

Illumina, BGI/MGI, and Element Biosciences



Strong Brand Equity - Globally

Featured in WSJ, NY Times, Wired, MIT Technology Review, Nature



Advisory Board Key Opinion Leaders

George Church, Harvard Medical School
Russ Altman, Stanford University
Patrick Merel, Genomics Professional



ProPhase Supplements

PROPHASE SUPPLEMENTS

A line of dietary supplements dedicated to providing clinically tested products that we develop and market. Will leverage the comprehensive marketing campaign developed by DNA Complete, to include top influencers, etc.



LEGENDZ XL®

Male sexual health support.
Event based; clinically proven to promote healthy blood flow in < 60min with first use.



TRIPLE EDGE XL®


Daily energy and stamina support
Daily support; clinically proven to improve physical and mental energy while supporting healthy testosterone levels.

EQUIVIR

Equivir: compounds that have demonstrated potential activity against certain viruses associated with serious viral outbreaks. Equivir portfolio is designed to support the body's ability to impede virulence while also blocking multiple methods used by viruses to infect and replicate in host cells.

Acquired exclusive, worldwide development and commercial rights to Equivir inventions discovered by Global Research and Discovery Group, which is scientific think tank and research organization that works with BARDA, DARPA, and the Potomac Institute.

Blend of: Polyphenols, Myricetin, Hesperidin, Piperine.



23

EQUIVIR CLINICAL TRIAL **

Equivir Clinical Trials with Vedic Lifesciences

Goal of launching as a dietary supplement Q4 2024-Q1 2025.

Preliminary results*: Overall, in the initial 150 patient group, approx. 46 incidences of upper respiratory viral infections. 62.3% of the patients in the placebo group acquired a viral infection versus only 37.7% in the Equivir group.

Additional key statistics from the initial findings are:

- 38% of the placebo population acquired an upper respiratory viral infection vs 24% in the Equivir group.
- After 4 days of illness, only 3% of the Equivir group still had mild symptoms vs 55% in the placebo group.
- The average severity was 16% less severe when taking Equivir vs the placebo.
- No patients in the Equivir group became ill a second time while 2 patients in the placebo group had a second upper respiratory viral infection.

**Equivir is being developed with plans to market as an OTC dietary supplement. Therefore, the Company cannot make claims for the treatment or prevention of infections generally or with respect to any specific viruses and is not seeking the U.S. Food and Drug Administration's approval of Equivir as a drug. However, the Company plans to publish the results when both studies are completed.

*Preliminary results announced by ProPhase Labs on February 14, 2024: <https://www.globenewswire.com/en/news-release/2024/02/14/2829018/0/en/ProPhase-Labs-Announces-Preliminary-Positive-Results-for-Dietary-Supplement-Equivir.html>



24

EQUIVIR TIMELINE

Clinical study

Completed. Positive preliminary results. Final report anticipated Q4 2024.

E-commerce

- Online launch anticipated Q4 2024 - Q1 2025.
- Leverages comprehensive marketing campaign to include influencers, etc.

Retail

- Positioning for placement in the cough cold section of retail stores.
- Expecting retailers to conduct category reviews Q1 2025.
- Goal to start shipping to retailers in mid-2025.



COMPETENT AND PROVEN EXECUTIVE MANAGEMENT TEAM



Ted Karkus
Chairman & CEO
ProPhase Labs, Inc.

Ted Karkus, CEO and Chairman of ProPhase Labs, drives the company's diverse and synergistic businesses with his successful track record in biomedical and health companies. He transformed ID Biomedical's strategy and valuation from \$25 million to \$1.4 billion sale to GlaxoSmithKline. As CEO of ProPhase Labs, he restructured the go-to-market strategy for the flagship product Cold-EEZE, turned around and significantly grew revenues, ultimately selling it for \$50 million to Mylan.

ProPhase Labs is a biotech, genomics and diagnostics company with a commitment of growth, innovation, and execution excellence outlined in Ted's high growth roadmap. He pivoted into industry leading CLIA labs, and then further diversified by acquiring genomics leader Nebula Genomics. Constantly innovating, Ted then created ProPhase BioPharma to deliver antivirals, cancer tests and therapeutic cancer compounds. The new acquisitions and legacy businesses work to drive synergistic growth with multi-billion-dollar potential.

He holds a BS in Psychology from Tufts University with Magna Cum Laude Honors and an MBA in Finance from Columbia University School of Business with Beta Gamma Sigma Honors.



Jed Latkin
COO
ProPhase Labs, Inc.

Jed A. Latkin served as a director and Chief Executive Officer of Navidea from October 2018, until October 2021. Mr. Latkin has more than 28 years of experience in the financial industry supporting many investments in major markets including biotechnology and pharmaceuticals. He most recently was employed by Nagel Avenue Capital, LLC since 2010, and in that capacity he provided contracted services as a CEO/CFO for numerous healthcare related firms. He serves on the board of Windtree Therapeutics. He worked for over ten years in Investment Banking at Citigroup, Morgan Stanley and Fleet Boston Robertson Stephens. He also spent five years as a CPM for ING Investment Management. Mr. Latkin earned a B.A. from Rutgers University and a M.B.A. from Columbia Business School.



Jason Karkus
President
Nebula Genomics & DNA Complete

Jason was instrumental in the strong revenue growth at ProPhase Diagnostics, leading sales, business development, logistics operations, and account management. He oversaw the development of two CLIA-certified labs, generating approximately \$200 million in revenues since 2021. Jason developed and now oversees DNA Complete and DNA Expand.

Jason is a graduate of the University of Maryland.



Sergio Miralles
EVP/CIO
ProPhase Labs, Inc.

Sergio Miralles is an experienced IT Leader with over 12 years of experience in enterprise level Cybersecurity, Infrastructure, and Architecture. Sergio is responsible for ensuring a complete end-to-end technology solution that links its lab customers' patient data via an interface to efficiently process and report results.

Previously, Sergio founded and led a successful IT consulting firm overseeing 18 IT consultants. For the last five years, his primary focus has been on the medical, lab, and diagnostics business. Sergio holds several certifications from Cisco, ISC2, and CompTIA.



Lance Bisesar
Corporate Controller
ProPhase Labs, Inc.

Lance is an accomplished finance leader experienced in all areas of finance and accounting. Lance has over 17 years of experience in working with large brands, both public and private, of varying industries and sizes.

Prior to ProPhase Labs, Lance served in finance leadership roles at multiple large brand companies including Colgate-Palmolive, Casper Sleep, Newmark and Forest Laboratories, where he was responsible for all accounting matters including financial reporting, general accounting, and related internal controls functions. He began his career with five years in public accounting with Marcum LLP. Lance earned a BBA in accounting from Hofstra University. He is a certified public accountant and is a member of the American Institute of Certified Public Accountants.



CAPITALIZATION TABLE & BALANCE SHEET SUMMARY

Pre-Offering Capitalization Table ¹		Balance Sheet Summary	As of June 30, 2024
Common Shares	19,078,529	Cash and cash equivalents	\$1,780,000
Options (WAEP: \$6.64)	3,913,750	Total Assets	\$93,678,000
Warrants (WAEP: \$9.13)	376,000	Total Liabilities	\$49,602,000
Fully Diluted Shares Outstanding	23,368,279	Total Shareholder's equity	\$44,076,000

1. Excludes shares of common stock to be issued valued at \$2.0 million to the Stella Sellers for BE-smart upon the Commercialization Event. The "Commercialization Event" means the date on which Gross Revenue meets or exceeds \$5,000,000 in the aggregate.



27

INVESTMENT HIGHLIGHTS

Expanding Pharnaloz Manufacturing - One of the Largest Lozenge Manufacturing Companies in the U.S.

- Growing capacity to meet strong demand
- Continuously growing customer base as capacity expands
- Engaged ThinkEquity to explore strategic alternatives, including a potential sale

BE-Smart Esophageal Cancer Test: Multi billion-dollar target market and hired FHC, world class consulting firm. In collaboration with FHC, goal to attain a potential strategic partnership with one of numerous, large cancer diagnostic companies in 2025 as well as commercialize either as a laboratory developed test (LDT) or in compliance with the applicable FDA requirements.

DNA Complete is Well Positioned to Capitalize on the Future Growth of Genomics and Personalized Medicine.

- Proprietary state-of-the-art bioinformatics reporting platform
- Growing genomic database
- Direct-to-consumer opportunities

Equivir (OTC): Clinically studied dietary supplement with significant potential, leveraging existing infrastructure. Goal to commercialize Q4 2024/Q1 2025.

Competent and Proven Executive Management Team for more than a decade.

28



Thank You



ProPhaseLabs.com

TED KARKUS
Chairman & CEO
711 Stewart Ave., Suite 200
Garden City, NY 11530

INSTITUTIONAL INVESTOR RELATIONS
267-880-1111
investorrelations@prophaselabs.com

RETAIL INVESTOR RELATIONS
John Boidman
Renmark Financial Communications
514-939-3989
jboidman@renmarkfinancial.com